The short answer: Leptomeningeal disease (also called leptomeningeal carcinomatosis or leptomeningeal metastases) occurs when cancer spreads to the fluid-filled membranes surrounding the brain and spinal cord. It is one of the most serious cancer complications, causing rapidly progressive neurological symptoms. End-of-life care focuses on managing these symptoms while supporting patients and families through a diagnosis that can be overwhelming.

What to Expect With Leptomeningeal Disease (Leptomeningeal Carcinomatosis) End-of-Life Care

Leptomeningeal disease (LMD) occurs when cancer cells infiltrate the cerebrospinal fluid (CSF) and spread along the surfaces of the brain and spinal cord. It complicates approximately 5-8% of all cancers, most commonly breast cancer, lung cancer, and melanoma. The prognosis is generally poor — median survival without treatment is 4-6 weeks; with treatment, 3-6 months for most patients.

Understanding Leptomeningeal Disease

Unlike brain metastases (distinct tumor masses), LMD involves diffuse coating of the brain and spinal cord surfaces by cancer cells. This creates multifocal neurological problems because it disrupts CSF flow and damages nerves throughout the neuraxis. Diagnosis is by CSF cytology (lumbar puncture) or MRI with gadolinium contrast.

Symptoms of Leptomeningeal Disease

LMD produces a characteristic syndrome of simultaneous symptoms at multiple neurological levels:

Cerebral symptoms: Headache (often worse with position change), altered cognition, personality change, seizures, visual disturbances.

Cranial nerve symptoms: Double vision, facial numbness/weakness, hearing loss, swallowing difficulty, voice changes.

Spinal symptoms: Limb weakness, sensory changes, bowel and bladder dysfunction, back or neck pain.

Treatment Options for Symptom Management

Corticosteroids: Dexamethasone reduces inflammation and may temporarily improve symptoms. It is often used to maintain quality of life.

Intrathecal chemotherapy: Direct injection of chemotherapy into the CSF (via lumbar puncture or Ommaya reservoir) may slow progression in some cases. Benefit is modest in most patients.

Radiation: Whole-brain radiation or targeted radiation to symptomatic areas may provide temporary relief.

Targeted therapy/immunotherapy: For cancers with known targets (HER2-positive breast cancer, EGFR-mutated lung cancer), targeted agents with CNS penetration may help.

When to Transition to Comfort Care

Given the poor prognosis of LMD and the burden of treatment (intrathecal chemotherapy requires repeated lumbar punctures or neurosurgical device placement), many patients and families choose comfort-focused care after discussion. The trajectory is often rapid, making early advance care planning essential.

Family and Caregiver Support

Leptomeningeal disease progresses rapidly and causes visible neurological changes that can be frightening for families. Hospice provides both symptom management expertise and family education about what to expect. Death doulas can support the emotional processing of a diagnosis that may allow very little time.

Frequently Asked Questions

What is leptomeningeal disease?

Leptomeningeal disease (LMD) occurs when cancer cells spread to the cerebrospinal fluid (CSF) and the meninges — the membranes coating the brain and spinal cord. Cancer cells coat brain and spinal surfaces rather than forming discrete masses. It most commonly complicates breast cancer, lung cancer, and melanoma. It causes multiple simultaneous neurological symptoms and has a poor prognosis.

What are the symptoms of leptomeningeal carcinomatosis?

LMD causes simultaneous symptoms at multiple neurological levels: headache and altered cognition from cerebral involvement, double vision, facial weakness, and swallowing problems from cranial nerve involvement, and limb weakness, sensory changes, and bowel/bladder dysfunction from spinal involvement. This combination of problems at multiple levels simultaneously is characteristic of LMD.

How is leptomeningeal disease diagnosed?

LMD is diagnosed primarily by MRI of the brain and spine with gadolinium contrast (showing meningeal enhancement) and by lumbar puncture with CSF analysis (cytology showing cancer cells in the spinal fluid). CSF cytology is positive in only about 50-75% of cases on the first tap; repeat sampling improves sensitivity. MRI findings combined with clinical symptoms are often sufficient for diagnosis.

What is an Ommaya reservoir?

An Ommaya reservoir is a small dome-shaped device surgically implanted under the scalp that connects to the brain's ventricular system. It allows repeated access to the CSF for intrathecal chemotherapy delivery without repeated lumbar punctures. It provides a more consistent and comfortable route for ongoing intrathecal treatment if chemotherapy is chosen.

How much time do patients have with leptomeningeal disease?

Without treatment, median survival with leptomeningeal disease is approximately 4-6 weeks. With treatment (intrathecal chemotherapy, radiation, targeted therapy if applicable), median survival is 3-6 months for most patients, with some patients living longer — particularly those with HER2-positive breast cancer responding to targeted intrathecal therapy. The trajectory is often rapid. Discussing goals of care and hospice options early is important.

Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.